BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

NanoSmart Pharmaceuticals, Inc. to Present as Top Innovator Company at New England Venture Summit, December 5


12/4/2012 10:36:27 AM

LAGUNA HILLS, Calif., Dec. 3, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, has been selected as a Top Innovator to present at the New England Venture Summit on Wednesday, December 5 in Boston, MA. Dr. Smith will discuss NanoSmart Pharmaceuticals' novel drug-delivery platform utilizing a human-derived antinuclear antibody that targets areas of necrosis present in all solid tumors. The presentation will include current status and planned development milestones, while explaining the benefits of reformulating existing drugs using NanoSmart's tumor targeting platform.

"There is a need for new and more-effective therapeutic products across all types of cancers; but particularly for those rare cancers that are often overlooked and/or underserved," said Dr. Smith. "We are pleased with the progress we are making in developing our pipeline and the success of our initial preclinical studies. Our ability to non-specifically target cancer tumors affords us the opportunity to rapidly commercialize new treatments for a wide range of pediatric/orphan indications."

Upon conclusion, details from the presentation and additional materials will be made available by request.

ABOUT NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc.,a private biotechnology company, is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of cancer and other diseases. NanoSmart has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of its lead candidate drug products.

This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

SOURCE NanoSmart Pharmaceuticals, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->